Bio Essence Corporation
BIOE
$0.206
-$0.008-3.74%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -41.25% | -104.85% | -101.23% | -67.98% | -11.28% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -41.25% | -104.85% | -101.23% | -67.98% | -11.28% |
| Cost of Revenue | -62.54% | -37.78% | 93.72% | 398.08% | -2.69% |
| Gross Profit | 67.13% | -23.42% | -76.50% | -49.61% | -60.43% |
| SG&A Expenses | 95.72% | -71.86% | -43.92% | -16.55% | -58.83% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 140.98% | -97.32% | -63.58% | -24.21% | -69.49% |
| Operating Income | -47.21% | 51.36% | -21.27% | -53.07% | 32.40% |
| Income Before Tax | -288.34% | -139.65% | -0.18% | -59.45% | 23.30% |
| Income Tax Expenses | -50.00% | -132.00% | -132.00% | -36.00% | -36.00% |
| Earnings from Continuing Operations | -287.00% | -138.43% | 0.57% | -58.70% | 23.36% |
| Earnings from Discontinued Operations | 145.28% | 0.77% | 0.77% | 0.77% | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -34.69% | -48.79% | 32.59% | 12.75% | -20.02% |
| EBIT | -47.21% | 51.36% | -21.27% | -53.07% | 32.40% |
| EBITDA | -48.94% | 44.61% | -28.40% | -55.27% | 31.39% |
| EPS Basic | -21.48% | -42.40% | 34.62% | 14.47% | -15.92% |
| Normalized Basic EPS | -16.67% | 35.71% | 10.00% | -49.15% | 27.27% |
| EPS Diluted | -21.48% | -42.40% | 34.62% | 14.47% | -15.92% |
| Normalized Diluted EPS | -16.67% | 35.71% | 10.00% | -49.15% | 27.27% |
| Average Basic Shares Outstanding | 8.84% | 6.66% | 10.65% | 9.58% | 5.79% |
| Average Diluted Shares Outstanding | 8.84% | 6.66% | 10.65% | 9.58% | 5.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |